{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    14,
    18
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_05",
        "affectedSection": "Study Visit Schedule",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Provided study visit scheduling flexibility by allowing optional phone visits for specific weeks."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_05",
        "affectedSection": "Section 1.3.3 - Other/Exploratory Objectives",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added exploratory endpoint for non-severe hypoglycemic events in subjects with specific HbA1c reduction."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_05",
        "affectedSection": "DKA Assessments and Reporting",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated guidance on insulin dose reductions, ketone monitoring, and DKA reeducation."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_05",
        "affectedSection": "Statistical Methods",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Replaced Dunnett procedure with Dunnett and Tamhane step-up and added ITT estimand analysis."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_03",
        "affectedSection": "Section 3.3.1 - Inclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified HbA1c stability requirements during lead-in phase based on EMA feedback."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_05",
        "reasonText": "To provide study visit scheduling flexibility for subjects during the 24 week double blinded treatment period.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_05",
        "reasonText": "Improved power and greater emphasis on primary endpoint through updated statistical procedures.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_03",
        "reasonText": "Regulatory authority (EMA) feedback requested removal of the requirement that HbA1c may not drop more than 0.5% during lead-in.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_05",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Week -1 Visit",
        "beforeText": "Not specified",
        "afterText": "Central laboratory HbA1c to <=10.5%",
        "summary": "Revised the upper range of the Week -1 Visit HbA1c."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.3.3",
        "beforeText": "Not specified",
        "afterText": "Tubal Ligation in this protocol is not considered surgical sterilization",
        "summary": "Clarified definition of surgical sterilization regarding tubal ligation."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_05",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Day 1 Visit",
        "beforeText": "PK Sampling required",
        "afterText": "PK Sampling removed",
        "summary": "Removed the PK Sampling requirement at the Day 1 visit."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_05",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.4.1",
        "beforeText": "Systemic corticosteroid therapy exclusion",
        "afterText": "Includes local injections such as intramuscular or intra-articular; adds drops to allowed topical corticosteroids",
        "summary": "Updated corticosteroid exclusion and allowance criteria."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_05",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Statistical Analysis",
        "beforeText": "Randomized subjects dataset",
        "afterText": "Full analysis dataset",
        "summary": "Updated terminology for the primary analysis population."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}